With the approval of capmatinib, how would you approach a newly diagnosed metastatic NSCLC with MET Exon 14 skipping mutation?

Somatic MET mutations leading to splicing-mediated loss of exon 14 and subsequent MET overexpression are an emerging therapeutic target present in 2-4% of lung adenocarcinomas (1, 2). MET tyrosine kinase inhibitor (TKI) treatment was associated with improved overall survival in a retrospective study...